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Geneva, Switzerland; and n ObsEva S.A, Plan-Les-Ouates, Geneva, SwitzerlandObjective: To investigate the efﬁcacy and safety of repeated 12-week courses of 5 or 10 mg daily ulipristal acetate for intermittent
treatment of symptomatic uterine ﬁbroids.
Design: Double-blind, randomized administration of four 12-week courses of ulipristal acetate.
Setting: Gynecology centers.
Patient(s): Four hundred ﬁfty-one subjects with symptomatic uterine ﬁbroid(s) and heavy menstrual bleeding.
Intervention(s): Four repeated 12-week treatment courses of daily 5 or 10 mg ulipristal acetate.
Main Outcome Measure(s): Endometrial safety and general safety, laboratory parameters, amenorrhea, controlled bleeding, ﬁbroid
volume, quality of life (QoL), and pain.
Result(s): Efﬁcacy results, such as bleeding control and ﬁbroid volume reduction, were in line with previously published data.
Pain and QoL showed marked improvements from screening, even during the off-treatment intervals. The safety proﬁle of
ulipristal acetate was conﬁrmed, and repeated treatment courses did not increase the occurrence of adverse reactions. There
were no signiﬁcant changes in laboratory parameters during the study. The percentage of subjects with endometrial
thickness R16 mm was 7.4% (all subjects) after the ﬁrst treatment course and returned to below screening levels (4.9%) in
subsequent treatment courses. As in previous studies, ulipristal acetate did not increase the occurrence of endometrial
features of concern. The frequency of nonphysiological changes did not increase with repeated treatment. They wereReceived June 25, 2015; revised September 18, 2015; accepted September 21, 2015; published online October 23, 2015.
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ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSEobserved in 17.8% and 13.3% of biopsies after treatment courses 2 and 4, respectively, and were reversible after treatment
cessation.
Conclusion(s): The results of this study demonstrate the efﬁcacy and further support the safety proﬁle of repeated intermittent treat-
ment of symptomatic ﬁbroids with ulipristal acetate.
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scanner” in your smartphone’s app store or app marketplace.U terine ﬁbroids are benign smooth muscle tumors ofthe uterus (1). When symptomatic, they arefrequently responsible for heavy menstrual bleeding
(2), infertility (2), and a decreased quality of life (3) (QoL). Uli-
pristal acetate (UPA) is a possible option for medical therapy.
UPA is a steroid compound with the main pharmacodynamic
property of reversibly blocking the progesterone (P) receptor
in its target tissue, acting as a potent orally active P receptor
modulator. It belongs to the class of selective P receptor mod-
ulators (SPRMs).
UPA is indicated for intermittent and preoperative treat-
ment of moderate to severe symptoms of uterine ﬁbroids in
adult women of reproductive age.
In the two short-term phase III studies for European regis-
tration PEARL I (4) (comparator: placebo) and PEARL II (5)
(active comparator: leuprolide acetate; a GnRH agonist
authorized for preoperative treatment of ﬁbroids), UPA was
shown to be effective in controlling uterine bleeding related
to myomas, to reduce myoma size, and to have a good safety
proﬁle. In clinical studies, SPRM administration has been
associated with a pattern of benign, nonphysiological, non-
proliferative, histologic features of the endometrium termed
P receptor modulator associated endometrial changes
(PAEC). These changes are characterized by cystic glandular
dilatation, apoptosis, low mitotic activity in the glands and
stroma, absence of stromal breakdown, and glandular crowd-
ing as clearly described by Williams et al. (6). The previous
clinical studies illustrated the reversibility of PAEC on endo-
metrial biopsies taken 6 months after UPA treatment
completion.
Two additional studies were initiated to assess the efﬁcacy
and safety of long-term, repeated, intermittent administration
ofUPA in patientswith symptomaticﬁbroids. PEARL III and its
extension (7) (long-term, intermittent, 10mg/day for 3months
with drug-free intervals) demonstrated that this dosing
regimen provided an effective and well-tolerated treatment
of the symptoms of uterine myomas with efﬁcient bleeding
control accompanied by a reduction in ﬁbroid volume.
The PEARL IV study, reported here, was the second
pivotal study to investigate the use of UPA for long-term
intermittent use and the ﬁrst one reporting results with the
authorized dose of UPA 5 mg. The main objective was to
assess the sustained efﬁcacy and safety of up to four intermit-166tent treatment courses with UPA 5 or 10 mg doses for uterine
bleeding, myoma volume, pain, QoL, and safety. The results
from the ﬁrst two treatment courses have previously been
published (8).
The primary null hypothesis was that there would be no
difference in the percentage of subjects who are in amenor-
rhea at the end of all four treatment courses for UPA 10 mg
compared with UPA 5 mg.
The data reported herein focus on the new ﬁndings from
treatment courses 3 and 4 as well as the four treatment
courses combined. With the recently registered indication of
intermittent treatment with UPA, the absence of endometrial
and laboratory safety ﬁndings associated with long-term
therapy is of special interest to clinicians.
MATERIALS AND METHODS
Study Design and Oversight
The study design and oversight of the phase III double-blind,
randomized PEARL IV study have previously been published
(7). PEARL IV was conducted in 46 centers in 11 European
countries from June 2012 to December 2014. The study was
approved by the independent ethics committees at each
participating site and was conducted in accordance with the
International Conference on Harmonization-Good Clinical
Practice Guidelines. The study was designed by the sponsor
(PregLem S.A.) with the involvement of academic investiga-
tors and a contract study statistician (CROS NT). Data were
collected by an independent Contract Research Organization
(ICON Clinical Research) and handled and analyzed by an in-
dependent Data Management organization (CROS NT). The
ﬁrst author vouches for the data accuracy and analysis and
the ﬁdelity of the study to the protocol.Study Population
Subjects enrolled in the study were premenopausal women
with at least one ﬁbroid R3 cm in diameter and none
>12 cm (as assessed by ultrasound), heavy menstrual
bleeding >100 (pictorial blood-loss assessment chart
[PBAC]), and uterine size <16 weeks of gestation. Eligible
subjects were aged between 18 and 50 years inclusive, with
body mass index 18–40 (kg/m2) and regular menstrual cycles
of 22–35 days with FSH%20 IU/L. Written informed consentVOL. 105 NO. 1 / JANUARY 2016
Fertility and Sterility®was obtained from all subjects. The main exclusion criteria
are listed in Supplemental Table 1.Randomization and Treatment
Subjects were allocated randomly by a web-integrated voice
response system in a 1:1 ratio to receive either 5 or 10 mg
of daily oral UPA and matching placebos for four 12-week
courses. UPA was started during the ﬁrst 4 days of menstru-
ation. Treatment courses were separated by a drug-free inter-
val. Subsequent courses started with the second menstruation
in the off-treatment period. Final follow-up was performed
after a 3-month drug-free period following the fourth treat-
ment course.
The sequence of treatments and biopsies is illustrated in
the Supplemental Figure 1.Assessment of Uterine Bleeding
Subjects recorded their bleeding intensity in a diary using an
8-day PBAC (Supplemental Fig. 2) at screening and during the
ﬁrst menstruation after treatment courses 1, 2, and 4. A PBAC
score >100 indicates menorrhagia. Outside this timeframe,
bleeding was recorded using a simpliﬁed semiquantitative
questionnaire containing four categories deﬁned as ‘‘no
bleeding’’, ‘‘spotting’’, ‘‘bleeding’’, or ‘‘heavy bleeding’’.Assessment of Endometrial Histology
Endometrial biopsies were obtained at screening and post-
treatment courses 2 and 4 and at 3 months post-treatment
follow-up. Evaluation of all biopsies was performed by three
independent pathologists who were blinded to visit sequence,
study-group assignment, each other's assessments, and
whether or not the subject had already received UPA treat-
ment. The sample collection of endometrial tissue was per-
formed by a gynecologist using a Pipelle de Cornier. To
allow collection of sufﬁcient biopsy material, the biopsy
was performed in the late proliferative or early secretory
phase of the menstrual cycle (i.e., at least 10–18 days after
the start of menstruation).Assessment of Fibroid Size and Endometrial
Thickness
Fibroid size and endometrial thickness measurements were
carried out by transvaginal ultrasound at screening, at the
end of treatment courses, and at follow-up. The ultrasonogra-
pher was blinded to the subject's treatment, and the same
operator performed each subject's ultrasound assessments.
At each visit, the three largest myomas and the endometrial
thickness were measured. For consistent myoma volume eval-
uation, the ultrasonographer was requested to record the my-
omas in three dimensions as well as the type of myoma
(submucosal, intramural, subserosal, pedunculated) and to
photo-document the measurements.Assessment of Pain and QoL
Pain and QoL assessments were carried out at screening, at
the start and end of each treatment course, and at post-VOL. 105 NO. 1 / JANUARY 2016treatment follow-up. Pain was assessed using a visual
analogue scale (VAS) ranging from 0 to 100, with higher
scores indicating more severe pain. QoL was assessed using
a validated questionnaire measuring uterine ﬁbroid symp-
tom severity (UFS-QoL), where lower scores indicate fewer
symptoms and where a level of 23 has been reported for
healthy subjects (3).Endpoints
The primary efﬁcacy endpoint for this study was the percent-
age of subjects in amenorrhea at the end of all four treatment
courses, where amenorrhea was classiﬁed as no more than
1 day of spotting in a 35-day period.
Secondary efﬁcacy endpoints included amenorrhea at the
end of each individual treatment course (1, 2, 3, and 4);
controlled bleeding in the last 56 days of each individual
treatment course (deﬁned as no episodes of heavy bleeding
and a maximum of 8 days of bleeding during the last
56 days of a treatment course); time to amenorrhea during
treatment courses 1, 2, 3, and 4; volume of three largest ﬁ-
broids; and pain and QoL. The results for treatment courses
1 and 2 have previously been published (8).
The safety endpoints included the number and proportion
of subjects withdrawing from treatment early for safety rea-
sons and the number and proportion of subjects experiencing
adverse events (AEs), including clinically signiﬁcant changes
in gynecological or breast examination, ovarian ultrasound,
electrocardiogram (ECG), laboratory parameters, vital signs,
and endometrial thickness and histology.Statistical Analysis
Efﬁcacy analyses were carried out on both the full analysis set
(FAS) and the per protocol set (PP). The population of primary
interest was the FAS, which was deﬁned as all randomized
and treated patients. The PP set was deﬁned as all subjects
who had completed all four treatment courses with no major
deviation in any treatment course. All statistical tests were
two-sided, with a 5% level of signiﬁcance. No adjustments
were made for the multiple testing of secondary endpoints.
In general, missing values were not imputed before analysis.
However, if only 3 consecutive days or less of the daily
bleeding pattern were missing, the missing values were
imputed with the greatest strength of bleeding immediately
before or after the period of missing days.
The results for binary endpoints (including the primary
efﬁcacy endpoint) for UPA 10 mg versus UPA 5 mg were
compared using c2-tests, with conﬁdence intervals of the dif-
ference calculated using the Newcombe-Wilson score method
(9). The change in total ﬁbroid volume and uterine volume
was analyzed via repeated-measures analysis of covariance
after a log-transformation, with the results back-
transformed before presentation. The change from baseline
in PBAC scores was analyzed via the Wilcoxon rank-sum
test with the Hodges-Lehmann estimator (and corresponding
Moses conﬁdence interval) used for the differences in me-
dians (10).167
ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSEAssuming a drop-out rate of approximately 10%, 444
subjects were to be randomized for the study to have >85%
power to detect an absolute difference in the primary
endpoint of R14%. This level of absolute difference was
based on the results of the previous registration studies and
was therefore of clinical relevance (5).RESULTS
Patients
Demographic and baseline characteristics were comparable
across the two treatment groups. All patients had moderate
to severe bleeding, and many had considerable pain as well
as impaired QoL (Supplemental Table 2). Seventy-ﬁve percent
of patients completed all four treatment courses. Treatment
compliance across both groups was high (R80%), and the
inter-treatment intervals were on average 51–56 days
between each treatment course for both groups.Efﬁcacy
All efﬁcacy results are presented for the FAS1 population,
where subjects had to have started at least the ﬁrst treatment
course, unless other indicated. The percentages of subjects
identiﬁed as being in amenorrhea for individual treatment
courses 1, 2, 3, and 4 were 71.8%, 74.1%, 73.3%, and 69.6%
in the 5 mg group and 82.6%, 82.2%, 78.3%, and 74.5% in
the 10 mg group, respectively. A statistically signiﬁcant dif-
ference was detected between the two treatment groups atTABLE 1
Key efﬁcacy outcomes (FAS 1 unless otherwise speciﬁed).
Variable
UPA 5 mg
(n[ 228)
Primary endpoint: amenorrhea at the end of all four treatment courses, n/
FAS 1a 95/195 (48.7)
FAS 4b 94/150 (62.7)
PP set 4c 94/149 (63.1)
Secondary endpoints
Controlled bleeding
Controlled bleedingd at the end of all four
treatment courses, n/N (%)
106/158 (67.1)
Controlled bleedingd at the end of treatment
course 4, n/N (%)
148/202 (73.3)
PBAC
PBAC scores, ﬁrst menses postscreening,
baseline actual, mean (median)
300.2 (224.0)
PBAC scores, ﬁrst menses post-treatment
course 4, mean (median)
139.7 (77.5)
Total volume of three largest ﬁbroids, cm3
End of treatment course 4 %CFB, median (IQR) 71.8 (87.6 to 3
Follow-up %CFB, median (IQR) 65.0 (85.1 to 2
Fibroid volume reductionR25%: end of treatment
course 4, n/N (%)
135/166 (81.3)
Note: If a woman had more than 3 consecutive missing days in the last 35 d of a treatment course, th
these last 35 d (subject is not in amenorrhea). Sensitivity analyses for this endpoint are reported in the
endpoints can be found in Supplemental Table 3. IQR ¼ interquartile range; CFB ¼ change from b
a FAS 1 is deﬁned as all subjects who received study treatment at least once for treatment course 1
b FAS 4 is deﬁned as all subjects who received study medication in the fourth treatment course at
c PP set 4 is deﬁned as all subjects who received study medication in the fourth treatment course f
d Controlled bleeding was deﬁned as no episodes of heavy bleeding and a maximum of 8 d of ble
e Ratio of UPA 10 mg ratio to baseline to UPA 5 mg ratio to baseline (95% CI).
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168the end of course 1 (P¼ .011) but not at the end of treatment
courses 2, 3, and 4 (Table 1 and Supplemental Table 3).
Of all subjects having started treatment, 48.7% in the
5 mg group and 60.5% in the 10 mg group were in amenor-
rhea in all four treatment courses (1, 2, 3, and 4 combined).
A statistically signiﬁcant difference was found between the
two treatment groups (P¼ .027). To avoid the impact of drop-
outs, the same analysis was also performed on the FAS4,
where subjects had to have started the fourth treatment
course, and the PP set 4 (PP4), where subjects had to be at least
80% compliant in each of the four courses with no major pro-
tocol deviations. For FAS 4 and for PP4, the percentage of
subjects assessed as being in amenorrhea at the end of all
four treatment courses was 62.7% and 63.1% in the 5 mg
and 72.1% and 73.2% in the 10 mg groups, respectively. No
statistically signiﬁcant difference was found between the
two treatment groups for either of these populations
(Table 1 and Supplemental Table 3).
The percentage of patients with controlled bleeding in the
last 56 days for individual treatment courses ranged from
73.3% to 93.4% across both treatment groups, with corre-
sponding median times to amenorrhea of 4–6 days in all
groups for each treatment course. No statistically signiﬁcant
differences were detected between the two treatment groups
at any of the time points (Table 1 and Supplemental Table 3).
PBAC was measured at screening and after courses 1, 2,
and 4 to assess the level of menstrual bleeding. In the 5-mg
group, the mean (median) levels at screening were 300.2
(224.0), and these decreased with each subsequent course toUPA 10 mg
(n[ 223)
Difference (95% CI)
(UPA 10 mg vs. UPA 5 mg)
P
value
N (%)
112/185 (60.5) 11.8 (1.9–21.8) .027
106/147 (72.1) 9.4 (1.2 to 20.0) .107
104/142 (73.2) 10.2 (0.5 to 20.8) .084
105/146 (71.9) 4.8 (5.5 to 15.2) .430
144/192 (75.0) 1.7 (6.9 to 10.4) .781
304.0 (214.5) NA NA
128.2 (76.0) 11.0 (49.0 to 26.0) .563
2.6) 72.7 (87.5 to 47.0) 0.88 (0.69–1.13)e .314
8.4) 67.4 (87.4 to 44.6) 0.87 (0.67–1.14)e .314
150/170 (88.2) NA NA
e amenorrhea assessment was left as missing, unless the women had reported bleeding during
Supplemental Material (available online). Results of additional time points and other secondary
aseline; %CFB ¼ percent change from baseline; NA ¼ no formal statistical analysis.
.
least once.
or at least for 56 d.
eding during the last 56 d of a course of treatment.
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Fertility and Sterility®levels of 139.7 (77.5) after course 4. The same pattern was also
seen in the 10-mg group (screening, 304.0 [214.5]; after
course 4, 128.2 [76.0]). No statistically signiﬁcant differences
were detected between the two treatment groups at any of the
time points (Table 1 and Supplemental Table 3).
Clinically signiﬁcant reduction of R25% volume of the
three largest ﬁbroids was reported after each treatment
course. In both groups, the percentage of subjects with a clin-
ically signiﬁcant reduction increased from course 1 to course
4. In the 5-mg group, the percentages increased from 62.3%
after course 1 to 78.1% after course 4. Similarly, in the 10-
mg group, the percentages increased from 66.5% to 80.5%.
(Table 1 and Supplemental Table 3). Further examination
showed that at the end of four treatment courses, 73.5% of
all subjects had a ﬁbroid volume reduction of R25% and
were in amenorrhea (Supplemental Fig. 4).
In addition, the percentage of subjects with a clinically
signiﬁcant volume reduction R50% increased from course
1 to course 4 in both treatment groups (Supplemental Table 3).
Pain scores improved in both groups during treatment;
the median overall pain scores in the 5- and 10-mg groups
at screening were 39 and 43, respectively, and ranged from
5 to 7 during treatment. Even during the off-treatment pe-
riods, including follow-up, the median pain ranged from 9.0
to 22.5. No statistically signiﬁcant differences were detected
between the two treatment groups at any of the time points
(Supplemental Tables 4 and 5).
Similarly, median UFS-QoL symptom severity scores of
50 at screening corresponded well to published symptom
severity scores for ﬁbroid patients (3). During treatment, me-
dian scores from 12.5 to 15.6 (which are scores comparable to
those of healthy subjects [3]) indicated the important reduc-
tion of symptom severity in both groups. Even during the
off-treatment periods, including follow-up, the median
symptom severity score ranged from 18.8 to 31.3. No statisti-
cally signiﬁcant differences were detected between the two
treatment groups at any of the time points (Supplemental
Tables 4 and 5).Endometrial Safety
At screening for study eligibility, endometrial biopsies for a
total of 493 subjects were reviewed by the central laboratory.
Of these, nine (1.8%) subjects were not eligible for the study
owing to abnormal ﬁndings (8 [1.6%] diagnoses of simple
non-atypical hyperplasia and one diagnosis of complex
non-atypical hyperplasia).
A consensus diagnosis (at least two out of three patholo-
gists in agreement) of benign endometrium was reached by
the independent pathologists for all subjects accepted into
the study. Benign polyps were reported in seven (1.7%)
subjects.
One subject from the 5-mg group had a diagnosis of com-
plex atypical hyperplasia during the study. At follow-up and
without any further medical or surgical intervention, this sub-
ject had a consensus diagnosis of benign endometrium. Four
other subjects were reported to have benign polyps, and one
subject from the 5-mg group was reported to have a hyperpla-
sic polyp.VOL. 105 NO. 1 / JANUARY 2016All cases of hyperplasia observed after treatment
(including the cases previously reported [7]) returned to
benign endometrium under continued treatment (four
courses) and/or during the follow-up period. One case of hy-
perplasia was reported in the follow-up biopsy (3months after
treatment course 4). For this subject, all previous biopsies
(including after treatment course 4) had been diagnosed as
benign endometrium by the three independent pathologists.
The occurrence of nonphysiological endometrial changes
was observed in 7.8% of the 5-mg group and 8.4% of the 10-
mg group at screening. As expected, after treatment with UPA
nonphysiological changes increased, but this increase was in-
dependent of the dose and the number of treatment courses.
After treatment course 2, nonphysiological endometrial
changes were observed in 16.3% and 19.2% of the biopsies
for the 5- and 10-mg groups, respectively, decreasing to
16.2% and 10.3% after treatment course 4 (Table 2).
At follow-up, in 286 biopsies adequate for review, non-
physiological changes were observed in 9.0% and 6.3% of
the biopsies for the 5- and 10-mg groups, respectively, which
compares to the observed values at screening.
During the study, the median endometrial thickness re-
mained between 7 and 8 mm. The percentage of subjects
with endometrial thicknessR16 mm was 7.4% (all subjects)
after the ﬁrst treatment course and returned to below
screening levels (4.9%) in subsequent treatment courses.
(Fig. 1 and Supplemental Table 3).Laboratory Parameters
The median Hb value at screening was 12.55 and 12.40 g/dL
for subjects from the 5- and 10-mg groups, respectively. From
treatment course 1 to treatment course 4, Hb levels increased
compared with screening values, reaching a peak at the end of
treatment course 4, with median levels for the 5- and 10-mg
groups of 13.10 and 13.35 g/dL, respectively (Supplemental
Table 6).
The median Hct values at screening were 0.40 for both the
5- and 10-mg groups. During the study, Hct levels increased
to reach a peak at the end of treatment course 2 for both treat-
ment groups, median 0.42 (Supplemental Table 6).
E2 levels remained stable in both treatment groups across
the study period (Supplemental Table 6).
At screening, four (1.8%) and seven (3.2%), subjects had
high values (>ULN, Upper Limit of Normal) for aspartate
aminotransferase (AST) in the 5- and 10-mg groups, respec-
tively. At the follow-up assessment, approximately 3 months
after end of study treatment, four (2.4%) and six (3.6%) had
high values in the two respective groups. For alanine amino-
transferase (ALT), at screening four (1.8%) and two (0.9%) had
high values, with two (1.2%) and four (2.4%) of patients also
reporting high values at the follow-up assessment in the
5- and 10-mg groups, respectively. The number of subjects
with high gamma glutamyl transferase (GGT) levels at
screening were 14 (6.1%) and 10 (4.5%) for the 5- and 10-
mg groups, respectively, with 12 (7.1%) and 15 (9.0%) also re-
porting high levels at follow-up (Supplemental Table 7).
For all lipid parameters, the levels for subjects from the 5-
and 10-mg groups were comparable during the study. At169
TABLE 2
Summary of endometrium biopsy results (safety population).
Treatment group Category Classiﬁcation
Visits
Screening
After
treatment 2
After
treatment 4 Follow-up
UPA 5 mg
(n ¼ 230)
Endometrium biopsy performed Yes 230 193 168 164
Specimen adequatea Yes 219 (95.2) 178 (92.2) 148 (88.1) 144 (87.8)
Primary diagnosisb Benign endometrium 219 (100.0) 176 (98.9) 147 (99.3) 143 (99.3)
Hyperplasia 0 1 (0.6) 1 (0.7) 1 (0.7)
Simple, nonatypical 0 1 (0.6) 0 0
Complex, nonatypical 0 0 0 0
Simple, atypical 0 0 0 0
Complex, atypical 0 0 1 (0.7) 1
Malignant neoplasm 0 1 (0.6) 0 0
Endometrial
adenocarcinomac
0 1 (0.6) 0 0
Other malignant neoplasm 0 0 0 0
Polypsb Absent 216 (98.6) 176 (98.9) 146 (98.6) 143 (99.3)
Present: benign 3 (1.4) 2 (1.1) 1 (0.7) 1 (0.7)
Present: hyperplasic 0 0 1 (0.7) 0
Present: carcinomatous 0 0 0 0
Of those with Benign
endometrium
Nonphysiological changes
observed by two or three
pathologistsb
17 (7.8) 29 (16.3) 24 (16.2) 13 (9.0)
UPA 10 mg
(n ¼ 221)
Endometrium Biopsy performed Yes 220 194 163 160
Specimen adequatea Yes 203 (92.3) 182 (93.8) 145 (89.0) 142 (88.8)
Primary Diagnosisb Benign endometrium 203 (100.0) 180 (98.9) 145 (100.0) 142 (100.0)
Hyperplasia 0 2 (1.1) 0 0
Simple, nonatypical 0 1 (0.5) 0 0
Complex, nonatypical 0 0 0 0
Simple, atypical 0 1 (0.5) 0 0
Complex, atypical 0 0 0 0
Malignant neoplasm 0 0 0 0
Endometrial adenocarcinoma 0 0 0 0
Other malignant neoplasm 0 0 0 0
Polypsb Absent 199 (98.0) 180 (98.9) 142 (97.9) 142 (100)
Present: benign 4 (2.0) 2 (1.1) 3 (2.1) 0
Present: hyperplasic 0 0 0 0
Present: carcinomatous 0 0 0 0
Of those with benign
endometrium
Nonphysiological changes
observed by two or three
pathologistsb
17 (8.4) 35 (19.2) 15 (10.3) 9 (6.3)
Note: Numbers in parentheses are percents. In addition to cases of hyperplasia captured at nominated protocol visits, one consensus diagnosis of simple atypical hyperplasia was reported after the
unscheduled histology review of material taken by curettage after the SAE of menorrhagia after treatment course 1. At early termination visit approximately 1 mo later, this subject had a consensus
diagnosis of benign endometrium.
a Denominator of percentage is the number of subjects that have an endometrium biopsy performed.
b Denominator of percentage is the number of subjects with an adequate specimen.
c Preexisting condition.
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ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSEscreening, the median levels of total cholesterol for the two
groups were 4.93 and 5.03mmol/L. The levels remained stable
at each subsequent assessment, with medians ranging from
5.21 to 5.48. The median levels of low-density lipoprotein
cholesterol for the two groups were 2.90 and 2.97 mmol/L
at screening, and these remained stable at each subsequent
assessment, with medians ranging from 2.99 to 3.23.
Following the same pattern, at screening, the median levels
of high-density lipoprotein cholesterol for the two groups
were 1.61 and 1.55 mmol/L. The levels remained stable at
each subsequent assessment across the treatment groups,
with medians ranging from 1.64 to 1.71. Levels of triglycer-
ides increased slightly during the study. At screening, the me-
dians in the 5- and 10-mg groups were 0.87 and 0.91 mmol/L,
respectively, increasing to median levels of 0.97 and 1.08 at
the follow-up assessment (Supplemental Table 6). Further-170more, at screening, 27 (11.8%) and 30 (13.7%) subjects had
high values (>ULN) for triglycerides in the 5- and 10-mg
groups, respectively. Similarly at the follow-up assessment,
27 (16.0%) and 26 (15.6%) had high values in the two respec-
tive groups (Supplemental Table 7).General Safety
The numbers (percentages) of subjects who reported AEs dur-
ing treatment courses 1, 2, 3, and 4 were 102 (44.3%), 59
(27.4%), 32 (16.6%), and 43 (23.9%), respectively, for the 5-
mg group and 98 (44.3%), 60 (29.3%), 38 (20.2%), and 33
(19.0%), respectively, for the 10-mg group (Supplemental
Table 8). The numbers (percentages) of subjects who reported
AEs considered as treatment related by the investigator dur-
ing treatment courses 1, 2, 3, and 4 were 47 (20.4%), 28VOL. 105 NO. 1 / JANUARY 2016
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Fertility and Sterility®(13.0%), 9 (4.7%), and 11 (6.1%), respectively, for the 5-mg
group and 43 (19.5%), 22 (10.7%), 12 (6.4%), and 14 (8.0%),
respectively, for the 10-mg group. The vast majority of AEs
(97.6%) were of mild or moderate severity in both groups.
Headaches and hot ﬂushes were the most frequently re-
ported AEs (%11% of subjects in any treatment course),
although the frequency of these events decreased with each
successive treatment course (Supplemental Table 8). Breast
pain/discomfort was observed in %3% of subjects, with a
decrease in frequency for each successive treatment course
(%1% by treatment course 4). In total, 114 (25.3%) patients
discontinued the study at any time and for any reason. Of
those, 32 patients discontinued due to AEs, of which 21
were considered related to study drug. No difference between
treatment groups was observed. Overall 34 serious adverse
events (SAEs) were reported; 21 in the 5-mg group and 13
in the 10-mg group. Of these, 13 were classiﬁed by the inves-
tigator as related to study medication: nine in the 5 mg-group
(ﬁve menorrhagia, one bipolar disorder, one spontaneous my-
oma expulsion, one abdominal pain, one back pain) and four
in the 10-mg group (one partial expulsion, one spontaneous
myoma expulsion, one myoma necrosis, one endometriosis).
No safety concerns were identiﬁed from physical exami-
nation, vital signs, ovarian ultrasound, and ECGs.DISCUSSION
The PEARL IV study was designed to investigate the safety
and efﬁcacy of long-term, repeated intermittent treatment
with four 12-week treatment courses of daily oral administra-
tion of either 5 or 10 mg of UPA in subjects with uterine ﬁ-
broids. This is the ﬁrst full clinical trial reporting the use of
UPA 5 mg in a long-term repeated intermittent manner.
Alternative treatment options previously available for theVOL. 105 NO. 1 / JANUARY 2016medical management of ﬁbroids, such as GnRH agonists,
could be used only for a limited period owing to the AE proﬁle
and rapid ﬁbroid regrowth after treatment cessation (5).
Among the latest possible therapeutic options (11), UPA has
proved to be a suitable alternative for the medical manage-
ment of ﬁbroids.
Out of the 451 subjects with symptomatic uterine ﬁbroids
and conﬁrmed menorrhagia recruited, 75% of subjects re-
mained in the study on average a total of 20 months, demon-
strating a good compliance with the protocol considering the
duration of the study.
Investigation of the rate of amenorrhea during each treat-
ment course showed that both UPA 5 and 10 mg led to amen-
orrhea in a high percentage of subjects (R70%). Amenorrhea
was reached on average within 1 week, and post-treatment
menstrual bleeding was markedly reduced compared with
pretreatment bleeding.
A high percentage of subjects were in amenorrhea for all
treatment courses combined. The small observed difference
between the treatment groups was within the predeﬁned
acceptable difference of 14% and was therefore not deemed
to be clinically relevant. This was conﬁrmed by the analysis
of the group of subjects who had started all four courses,
which found no statistically signiﬁcant difference between
the groups.
An additional secondary endpoint of importance in as-
sessing the efﬁcacy of UPA is the evaluation of bleeding
control. No difference between the treatment groups was
seen, with both groups showing R73% of subjects having
bleeding control during each independent treatment course.
These data conﬁrm previously known data (4, 5, 7, 8)
regarding the efﬁcacy of UPA with regards to controlling
bleeding symptoms in subjects with symptomatic uterine
ﬁbroids.171
ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSEFurthermore, assessment of the blood loss during the ﬁrst
menstrual bleed after the treatment courses using the PBAC
showed a marked progressive reduction from baseline with
no difference between the two treatment groups.
Hb levels and associated hematology parameters
increased over the ﬁrst two treatment courses and were sus-
tained until follow-up.
The total volume of the three largest myomas was shown
to decrease after the ﬁrst treatment course and was seen to
further decrease after each subsequent treatment course.
The reduction in volume was maintained thereafter until the
end of study follow-up. A similar level of response was seen
from both treatment groups with no statistically signiﬁcant
differences between them at any visit during the study.
Furthermore, over 73% of all subjects had both ﬁbroid volume
reductionR25% at the end of four treatment courses in com-
bination with being in amenorrhea (Supplemental Fig. 4).
For pain and QoL, an important improvement was re-
corded during treatment in these assessments, reaching scores
reported for healthy individuals, in both treatment groups (3).
The changes in these measurements were of a similar level be-
tween the two treatment groups. The results therefore show
that the use of UPA results in an improvement in QoL and
control of pain, in comparison to baseline, even during the
off-treatment intervals.
After a transient increase in endometrial thickness in the
ﬁrst treatment course, fewer subjects had endometrial thick-
ness >16 mm after each successive treatment course. No
important differences with regards to endometrial thickness
were observed between the 5- and 10-mg groups.
Over the entire observation period, six cases of hyperpla-
sia were observed. All cases of hyperplasia observed after
treatment returned to benign endometrium under continued
treatment and/or during the follow-up period.
The occurrence of hyperplasia in a follow-up biopsy in a
subject having been exposed to four courses of UPA and for
whom all previous biopsies (including the one taken after
the end of treatment course 4) had been diagnosed as benign
endometrium by all pathologists illustrates that hyperplasia
can occur spontaneously in this population.
Overall, the occurrence of nonphysiological changes of
the endometrium was not increased with repetition of treat-
ment courses and returned to pretreatment levels within
3 months of completion of treatment.
Levels of E2 remained well above postmenopausal levels,
suggesting that bone mineral density will not be adversely
impacted by repeated intermittent use of UPA.
Mean levels of AST and ALT did not alter during the
study; however, some sporadic increases were seen in individ-
ual subjects. In no subject were increases in transaminases
associated with increases in bilirubin.
There were mild increases in mean cholesterol and tri-
glyceride values during the study. At screening, 41.4% of all
subjects had total cholesterol >ULN, and, as expected in
such a long-term study recruiting women predominantly in
their 40s, a number of subjects showed modest increases in
cholesterol over the duration of the study (approximately
20 months). However, the median ratio of total cholesterol/
high-density lipoprotein cholesterol remained virtually un-172changed and below the level at which the risk of cardiovascu-
lar disease is considered to be increased.
More on-treatment AEs were reported during treatment
course 1 than during subsequent treatment courses, and the
most frequently reported on-treatment AEs were headache
and hot ﬂush. No other AE occurred at a frequency of >4%
of subjects, and over 97% of all reported on-treatment AEs
were rated as being of mild or moderate severity. Overall, there
were no differences between the 5- and 10-mg dosing groups
with respect to the type, frequency, and severity of AEs.
Conclusions
The current manuscript summarizes the full efﬁcacy and safety
results of the ﬁrst randomized controlled trial using the
approved dose of 5 mg UPA in a repeated, intermittent therapy
setting (four courses) for the management of uterine ﬁbroids.
The administration of four 12-week treatment courses of
UPA at doses of 5 and 10 mg was well tolerated, with a high
level of treatment compliance. No differences between the 5
and 10 mg dosing groups were recorded in terms of safety
evaluations, which include a comprehensive evaluation of
the endometrial characteristics and laboratory parameters
observed with the long-term use of UPA.
In terms of efﬁcacy, both doses provided efﬁcient
bleeding control leading to amenorrhea in the majority of
subjects in each of the four treatment courses. This bleeding
control was achieved very rapidly and was accompanied by
a reduction in ﬁbroid volume and a reduction of pain associ-
ated with a clinically signiﬁcant improvement in QoL with
both doses. Furthermore, even during off-treatment periods,
the level of bleeding, pain, and QoL were still improved
compared with baseline. Myoma reduction was largely main-
tained during the off-treatment periods, and these effects were
sustained until the end of study follow-up, approximately
3 months after completion of the four treatment courses.
The results of this study therefore demonstrate the efﬁ-
cacy and further verify the safety proﬁle associated with
repeated intermittent treatment of symptomatic ﬁbroids
with UPA.
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SUPPLEMENTAL FIGURE 1
Schedule of treatments and visits.
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SUPPLEMENTAL FIGURE 2
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PBAC, one of the current standard methods used to objectively estimate menstrual blood loss and diagnose menorrhagia. The method that was
developed and validated by Higham and Janssen deﬁnes excessive bleeding as a PBAC score >100.
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SUPPLEMENTAL FIGURE 3
Screened
N=555
Patient disposition. Withdrawals are presented according to the timeframes in which they occurred, either during treatment or after treatment
completion for each course. Two subjects randomized to the UPA 10 mg group received UPA 5 mg treatment in error; these subjects are
included in the FAS sets according to randomization and in the safety set according to treatment received.
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SUPPLEMENTAL FIGURE 4
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